Objective Taking young patients with essential hypertension as an example, to explore the combined therapeutic effect of nifedipine controlled release tablets and irbesartan. Methods: Ninety-two patients treated in our hospital from April 2021 to November 2022 were randomly divided by 1:1, 46 cases in each group. One group was treated with nifedipine controlled release tablets and was recorded as the control group. One group was treated with irbesartan, which was recorded as observation group, and the effect of combined treatment was analyzed. Results: Systolic blood pressure and diastolic pressure in the observation group were lower than those in the control group (P＜0.05). There was no difference in heart rate between the two groups (P＞0.05). The levels of TNF-Alpha, IL-6 (interleukin-6) and hsCRP (serum C-reactive protein) in the observation group were lower than those in the control group (P＜0.05). The total effective rate of the observation group (95.65％) was higher than that of the control group (76.09％) (P＜0.05). There was no difference in ADR between the two groups (P＞0.05). Conclusion: Combined treatment can effectively stabilize the blood pressure level of patients, promote the remission of inflammatory response, effectively inhibit the progression of patients'' disease, and less toxic side effects, worthy of promotion.
万方数据